Navigation Links
Norovirus, AIDS vaccine and Hepatitis Virus

ch 2005 issue of the Journal of Virology.

Hepatitis B (HBV) and C (HCV) are viruses that infect the liver, and in some cases can cause liver failure requiring a transplant for survival. The protein interferon, produced by animal cells when they are invaded by viruses, is released into the bloodstream or intercellular fluid to induce healthy cells to manufacture an enzyme that counters the infection. One class of interferons (alpha) is used to treat chronic infection with HBV and HCV. There is a vaccine available to prevent the spread of HBV but not HCV.

In the study, a new class of interferons, interferon lambda, was tested for its ability to inhibit HBV and HCV replication. Results showed 90% inhibition of HBV after twenty-four hours and 90-99% inhibition in HCV five days posttreatment.

"We have demonstrated here that replication of HBV and HCV is sensitive to the antiviral activities of interferon lambda," say the researchers. "These results suggest the possibility that interferon lambda may be therapeutically useful in the treatment of chronic HBV or HCV infection."

(M.D. Robek, B.S. Boyd, F.V. Chisari. 2005. Lambda interferon inhibits hepatitis B and C virus replication. Journal of Virology, 79. 6: 3851-3854.)


'"/>

Source:American Society for Microbiology


Page: 1 2 3

Related biology news :

1. Research advances quest for HIV-1 vaccine
2. A much-needed shot in the arm for HIV vaccine development
3. Discovery of key proteins shape could lead to improved bacterial pneumonia vaccine
4. Gene vaccine for Alzheimers disease shows promising results
5. Influenza vaccine uses insect cells to speed development
6. HIV vaccine trial breaks ground for future research
7. Live vaccines more effective against horse herpes virus
8. NIAID begins clinical trial of West Nile virus vaccine
9. Designing vaccines by computer
10. Wake Forest scientists find new combination vaccine effective against plague
11. New vaccine means bye-bye to bacteria in the lung
Post Your Comments:
*Name:
*Comment:
*Email:
TAG: Norovirus AIDS vaccine and Hepatitis Virus

(Date:6/30/2015)... , June 30, 2015 To bolster its ... provider HYPR Corp. announced today the addition of two new ... serve as board advisor and David Raviv will ... team underscore HYPR Corp.,s commitment to providing the most secure ... Dimitri Sirota co-founded Layer 7 Technologies, a provider of ...
(Date:6/26/2015)... 26, 2015 ATL Technology, LLC, a top provider ... in single use solutions, headquartered in Springville, Utah ... California corporation with locations in ... Jose, Costa Rica ). This acquisition will ... with ATL Technology,s existing facility in Costa ...
(Date:6/25/2015)... , June 25, 2015  TAKE Solutions Ltd., ... patent by the United States Patent and Trademark Office ... This process leverages TAKE Solutions, Clinical Accelerators to reduce ... 50% (when compared to standardization without the accelerators), thus ... At the heart of the ...
Breaking Biology News(10 mins):HYPR Corp. Expands Biometric Authentication Team with Enterprise All Stars 2HYPR Corp. Expands Biometric Authentication Team with Enterprise All Stars 3ATL Technology Announces Acquisition of MedConx, Inc. and Expanded Global Footprint 2TAKE Solutions Awarded Patent By USPTO 2
... dangerous consequences of iron deficiencies is the fact that ... origin of the genetic iron overload disorder hereditary ... researchers from the European Molecular Biology Laboratory (EMBL) and ... HH is a liver disease. They report in the ...
... PITTSBURGH Scientists at Carnegie Mellon Universitys Molecular Biosensor ... proteins (FAPs) that will become a key component ... Carnegie Mellon. The FAPs, which can be used ... other biomolecules within living cells in real time, ...
... bisporus) has as much, and in some cases, more anti-oxidant ... is the foremost cultivated edible mushroom in the world with ... thought of as a poor relation to its more exotic ... But according to new research in SCIs Journal of the ...
Cached Biology News:Europe's most common genetic disease is a liver disorder 2Carnegie Mellon scientists develop fluorescent proteins for live cell imaging, biosensor design 2Carnegie Mellon scientists develop fluorescent proteins for live cell imaging, biosensor design 3
(Date:7/3/2015)... , July 3, 2015 /PRNewswire/ ... hakea verkossa osoitteessa  http://www.openinnovationinscience.at ... Innovation in Science" -jatkokoulutusohjelmaan 22.7.2015 ... Gesellschaftin (LBG) tekemän, kansainvälisiä tutkijoita ... terveystieteiden kaksi suurinta haastetta ovat ...
(Date:7/3/2015)...  Pomerantz LLP announces that a class action lawsuit ... the "Company")(NYSE: PBYI ) and certain of its ... Court, Central District of California , ... class consisting of all persons or entities who purchased ... 2015 inclusive (the "Class Period").  This class action seeks ...
(Date:7/2/2015)... July 2, 2015 Amici Procurement ... procurement company Amici Procurement has chosen Microsoft Cloud Solution ... move to Office 365.      (Logo: http://photos.prnewswire.com/prnh/20121126/579634) ... to medium-sized companies in the bio-tech sector with a ... the purchasing cycle to help them obtain best value. ...
(Date:7/1/2015)... 2015   Decision Resources Group finds ... Otezla are its oral administration, alternative mechanism of ... surveyed rheumatologists. Otezla was the first oral therapy ... active psoriatic arthritis in the United ... includes conventional oral treatments including disease-modifying antirheumatic drugs ...
Breaking Biology Technology:Maailman ensimmäinen tiedemiesten koulutukseen suunniteltu avoimen innovaation ohjelma käynnistyy 2Maailman ensimmäinen tiedemiesten koulutukseen suunniteltu avoimen innovaation ohjelma käynnistyy 3SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Puma Biotechnology, Inc. of Class Action Lawsuit and Upcoming Deadline - PBYI 2SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Puma Biotechnology, Inc. of Class Action Lawsuit and Upcoming Deadline - PBYI 3SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Puma Biotechnology, Inc. of Class Action Lawsuit and Upcoming Deadline - PBYI 4Biotech Procurement Company Moves to Office 365 with iomart 2Surveyed Rheumatologists Report That Otezla's Oral Administration is its Single Greatest Advantage Over Currently Available Treatment Options 2Surveyed Rheumatologists Report That Otezla's Oral Administration is its Single Greatest Advantage Over Currently Available Treatment Options 3
... NEW YORK, Aug. 11 /PRNewswire-Asia-FirstCall/ ... ("the Company" or "AOBO"), a pharmaceutical,company dedicated to improving ... range of prescription and over the counter ("OTC"),products in ... Board of,Directors of AOBO approved the engagement of Ernst ...
... , , SEATTLE, Aug. 11 ... 2 clinical trial of OMS302, the Company,s ophthalmologic PharmacoSurgery(TM) ... anti-inflammatory agent and an agent that causes pupil dilation ... , Omeros, Phase 1/Phase 2 trial ...
... , , , COLUMBIA, Md., ... MATK ), today announced the signing of a Joint Development Agreement ... applications. The partnership combines a broad technology platform and operational capabilities ... of sugars into biodiesel. , , Under ...
Cached Biology Technology:Omeros Announces Positive Clinical Results of Phase 1/Phase 2 Trial of OMS302 for Use During Ophthalmologic Surgery 2BP and Martek Biosciences Enter a Joint Development Agreement to Deliver Advanced Biodiesels 2BP and Martek Biosciences Enter a Joint Development Agreement to Deliver Advanced Biodiesels 3BP and Martek Biosciences Enter a Joint Development Agreement to Deliver Advanced Biodiesels 4